The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Insulin resistance and hepatic lipid accumulation constitute the metabolic underpinning of nonalcoholic steatohepatitis (NASH). We tested the hypothesis that saroglitazar, a PPAR α/γ agonist would improve NASH in the diet-induced animal model of NAFLD. Mice received chow diet and normal water (CDNW) or high fat western diet and ad lib sugar water (WDSW). After 12 weeks, WDSW fed mice were randomized to receive (1) WDSW alone, (2) WDSW + vehicle, (3) WDSW + pioglitazone or (4) WDSW + saroglitazar for an additional 12 weeks. Compared to mice on WDSW and vehicle controls, mice receiving WDSW + saroglitazar had lower weight, lower HOMA-IR, triglycerides, total cholesterol, and ALT. Saroglitazar improved steatosis, lobular inflammation, hepatocellular ballooning and fibrosis stage. NASH resolved in all mice receiving saroglitazar. These effects were at par with or superior to pioglitazone. Molecular analyses confirmed target engagement and reduced oxidative stress, unfolded protein response and fibrogenic signaling. Transcriptomic analysis further confirmed increased PPAR-target expression and an anti-inflammatory effect with saroglitazar. Lipidomic analyses demonstrated that saroglitazar also reduced triglycerides, diglycerides, sphingomyelins and ceramides. These preclinical data provide a strong rationale for developing saroglitazar for the treatment of NASH in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Self-citationNonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities
Sanyal, A. J., Campbell–Sargent, C., Mirshahi, F., Rizzo, W. B., Contos, M. J., Sterling, R. K., Luketic, V. A., Shiffman, M. L., & Clore, J. N. (2001) · Gastroenterology · doi:10.1053/gast.2001.23256 · Cited by 2,078
Self-citationSex differences in metabolic regulation and diabetes susceptibility
Tramunt, B., Smati, S., Grandgeorge, N., Lenfant, F., Arnal, J.-F., Montagner, A., & Gourdy, P. (2020) · Diabetologia · doi:10.1007/s00125-019-05040-3 · Cited by 923
Nrf2, the Master Regulator of Anti-Oxidative Responses
Vomund, S., Schäfer, A., Parnham, M., Brüne, B., & Von Knethen, A. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122772 · Cited by 752
Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease
Mota, M., Banini, B. A., Cazanave, S. C., & Sanyal, A. J. (2016) · Metabolism · doi:10.1016/j.metabol.2016.02.014 · Cited by 570
Self-citationA diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer
Asgharpour, A., Cazanave, S. C., Pacana, T., Seneshaw, M., Vincent, R., Banini, B. A., Kumar, D. P., Daita, K., Min, H.-K., Mirshahi, F., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.005 · Cited by 538
Self-citationLee, Y., Doumouras, A. G., Yu, J., Brar, K., Banfield, L., Gmora, S., Anvari, M., & Hong, D. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.10.017 · Cited by 371
Boettcher, E., Csako, G., Pucino, F., Wesley, R., & Loomba, R. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04912.x · Cited by 318
Metabolomic identification of subtypes of nonalcoholic steatohepatitis
Alonso, C., Fernández-Ramos, D., Varela-Rey, M., Martínez-Arranz, I., Navasa, N., Van Liempd, S. M., Lavín Trueba, J. L., Mayo, R., Ilisso, C. P., de Juan, V. G., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.01.015 · Cited by 263
Self-citationFruchart, J.-C. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-82 · Cited by 189
Cited by
Gawrieh, S., Noureddin, M., Loo, N., Mohseni, R., Awasty, V., Cusi, K., Kowdley, K. V., Lai, M., Schiff, E., Parmar, D., et al. (2021) · Hepatology · doi:10.1002/hep.31843 · Cited by 379
“Saroglitazar was also associated with reduction in homeostasis model assessment– insulin resistance (HOMAIR), TGs, total cholesterol, and metabolically active lipid species, including diglycerides, ceramides, and sphingomyelins, in mice with Western diet– induced NASH.(25) In this study, we evaluate the efficacy and s…”
BackgroundInfluentialBadmus, O. O., Hillhouse, S. A., Anderson, C. D., Hinds, T. D., & Stec, D. E. (2022) · Clinical Science · doi:10.1042/cs20220572 · Cited by 370
PPAR-γ signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets
Chen, H., Tan, H., Wan, J., Zeng, Y., Wang, J., Wang, H., & Lu, X. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108391 · Cited by 311
Nuclear receptors linking metabolism, inflammation, and fibrosis in nonalcoholic fatty liver disease
Puengel, T., Liu, H., Guillot, A., Heymann, F., Tacke, F., & Peiseler, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052668 · Cited by 95
Goyal, O., Nohria, S., Goyal, P., Kaur, J., Sharma, S., Sood, A., & Chhina, R. S. (2020) · Scientific Reports · doi:10.1038/s41598-020-78342-x · Cited by 83
Metadata
- Authors
- Kumar, D. P., Caffrey, R., Marioneaux, J., Santhekadur, P. K., Bhat, M., Alonso, C., Koduru, S. V., Philip, B., Jain, M. R., Giri, S. R., Bedossa, P., & Sanyal, A. J.
- Venue
- Scientific Reports
- Published
- 2020-06-09
- Volume
- 10
- Issue
- 1
- Pages
- 9330-9330
- ISSN
- 2045-2322 (ISSN-L)
- OpenAlex
- W3033969740
- Cited by
- 110
- References
- 12
- FWCI
- 11.37
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease. https://app.cochat.ai/papers/10.1038/s41598-020-66458-z
- The paper
- Kumar, D. P., Caffrey, R., Marioneaux, J., Santhekadur, P. K., Bhat, M., Alonso, C., Koduru, S. V., Philip, B., Jain, M. R., Giri, S. R., Bedossa, P., & Sanyal, A. J. (2020). The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease. Scientific Reports. https://doi.org/10.1038/s41598-020-66458-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.